Drug Trial Radar · NCT00396227
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,665
Actual
Start
Oct 2006
Primary completion
Oct 2007
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
Summary
As written by the sponsor on the registry.
This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.
Conditions
- Diabetes Mellitus, Type 2
Interventions
vildagliptinDrug
vildagliptin as add-on to metformin
thiazolidinedione (TZD)Drug
TZD add-on to metformin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HemoglobinA1c (HbA1c)Time frame: after 12 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Pharmaceuticals
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.